SA
AMPE

Shilanski & Associates’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Shilanski & Associates’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,124
Closed -$57K – 226
2022
Q3 		$57K Buy
+3,124
New +$109K 0.02% 137

Other funds holding AMPE

CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
ARG
Advisory Resource Group Tulsa, Oklahoma $665M AUM 29.27% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $108M AUM 54.47% 1-Year Est. Return

Shilanski & Associates's AMPE Position: Q4 2022 in Review

Shilanski & Associates sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q4 2022, closing a stake of 3,124 shares — an estimated $57K sold.

Shilanski & Associates first reported a position in AMPE in Q3 2022 and held it in 1 quarter. The position peaked at $57K in Q3 2022. 32 funds tracked by Wall St. Rank hold AMPE as of Q4 2022.

  • Shilanski & Associates reported no remaining Ampio Pharmaceuticals Inc. position as of Q4 2022 after selling out during the quarter.
  • Shilanski & Associates sold 3,124 Ampio Pharmaceuticals Inc. shares in Q4 2022, an estimated $57K.
  • Shilanski & Associates first reported a position in Ampio Pharmaceuticals Inc. in Q3 2022 and held it in 1 quarter.
  • Shilanski & Associates's Ampio Pharmaceuticals Inc. position peaked at $57K in Q3 2022.
  • 32 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q4 2022.

Based on Shilanski & Associates's 13F filing for Q4 2022, filed 31 Jan 2023.